Cleveland Clinic researchers find overly stringent eligibility criteria relevant to expected and observed adverse events may exclude specific patient populations from randomized clinical trials of hematologic malignancies.
Which research reports from the American Society of Hematology’s 2015 annual meeting are most likely to impact clinical practice in the near future? Cleveland Clinic Cancer Center’s hematology/medical oncology staff provides insight.
Cleveland Clinic researchers are using clinical and mutational data to enhance survival predictions for heterogeneously treated patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cleveland Clinic researchers are developing a non-toxic method to extend survival and response to 5-azacytidine, decitabine in treatment of myelodysplastic syndromes and acute myeloid leukemia.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic researchers find that analyzing molecular mutations in AML and MDS patients can help predict allogeneic HCT outcomes. Patients with complex karyotypes and TET2 mutations have poor overall survival.
Cleveland Clinic researchers find that thyroid cancer patients treated with surgery and radioactive iodine +/- external beam radiotherapy have an increased risk of MDS after two years.
In a large analysis of prescription patterns, Cleveland Clinic researchers find that fewer cancer patients than previously thought receive standard-of-care treatment for thrombosis.
A phase 2 trial of 277 patients with myelodysplastic syndromes including chronic myelomonocytic leukemias found no improvement in overall response rate with azacitidine in combination with lenalidomide or vorinostat.
Cleveland Clinic researcher among the team to find that many cancer patients at high risk for venous thromboembolism already have a blood clot before starting chemotherapy, suggesting benefit from anticoagulant prophylaxis.
Cleveland Clinic researchers find that eltrombopag may contribute to expansion of clones with possible leukemogenic mutations in patients with aplastic anemia. A case control study is underway.